Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics Sweden

View original content:https://www.prnewswire.co.uk/news-releases/calliditas-announces-positive-topline-results-of-phase-2-head-and-neck-cancer-trial-with-lead-nox-inhibitor-candidate-setanaxib-302136510.html